Statute Details
- Title: Medicines (Licensing, Standard Provisions and Fees) Regulations
- Act Code: MA1975-RG6
- Type: Subsidiary legislation (SL)
- Authorising Act: Medicines Act (Cap. 176), Section 74
- Current status: Current version as at 27 Mar 2026
- Primary subject matter: Licensing framework for medicines (product, import, wholesale dealing, manufacturing), standard licence conditions, and fees
- Key provisions (as reflected in the extract):
- Section 2: Definitions
- Section 3: Standard provisions for licences (including provisional licences) and special standard provisions for Chinese proprietary medicines
- Section 4: Grant of licences (licence grant mechanics/requirements)
- Section 5: Fees for applications and grant of licences/certificates
- Section 5A: Cost of evaluation
- Section 6: Offences for contravention/failure to comply with standard provisions
- Schedules:
- First Schedule: Standard provisions for product licence
- Second Schedule: Standard provisions for import licence
- Third Schedule: Standard provisions for wholesale dealer’s licence
- Fourth Schedule: Standard provisions for manufacturer’s licence
- Fifth Schedule: Fees
- Sixth Schedule: Repealed
What Is This Legislation About?
The Medicines (Licensing, Standard Provisions and Fees) Regulations (“the Regulations”) form a core part of Singapore’s medicines regulatory architecture. They sit under the Medicines Act and operationalise licensing by prescribing (i) the standard provisions that attach to different types of licences, and (ii) the fees payable for applications and grants. In practical terms, the Regulations translate the Medicines Act’s licensing powers into detailed, enforceable licence conditions.
The Regulations cover the lifecycle of regulated medicinal products through the supply chain: product licensing (for placing a product on the market), import licensing (for bringing products into Singapore), wholesale dealing licensing (for distribution), and manufacturing licensing (for production). Rather than leaving licence conditions to be negotiated case-by-case, the Regulations embed standard terms in schedules. This promotes consistency, predictability, and enforceability.
Importantly, the Regulations also include tailored standard provisions for Chinese proprietary medicines. These provisions reflect additional documentation and testing requirements and specific controls on dealing with licensed products. For practitioners, this means compliance obligations may differ depending on the product category and the licence type held.
What Are the Key Provisions?
1. Definitions and regulatory actors (Section 2). The Regulations define key terms used throughout, including “licensing authority” (the Chief Executive of the Authority), and references to regulatory concepts such as “major variation”, “psychotropic substance”, and “reference drug regulatory agency”. These definitions matter because they determine the scope of what must be disclosed, the regulatory comparisons that may be used, and the compliance posture expected of licence holders.
2. Standard provisions for licences (Section 3). Section 3 is the heart of the Regulations. It provides that, subject to an exception, the standard provisions for licences granted under Part II of the Medicines Act are those set out in the relevant schedules: First Schedule for product licences, Second Schedule for import licences, Third Schedule for wholesale dealer’s licences, and Fourth Schedule for manufacturer’s licences. The section also expressly includes provisional licences, meaning that interim licensing is not exempt from standard conditions.
Special regime for Chinese proprietary medicines (Section 3(2)–(4)). Section 3 contains a detailed set of modifications for Chinese proprietary medicines. For import licences relating to such medicines, the standard provisions in the Second Schedule apply except specified paragraphs. The extract shows that additional conditions include: (a) a requirement for the licence holder to seek prior approval from the licensing authority to deal with any medicinal product under the licence, and to provide information and documents within a time specified by the authority; (b) restrictions on importing/selling/supplying unless the approval remains valid and the holder complies with applicable written law; and (c) a post-import documentation and testing obligation.
The extract further illustrates a compliance mechanism that is highly practical for enforcement and for regulated entities: after import of a consignment, the licence holder must submit, within two months, specified declarations and test results. These include declarations relating to the absence of poisons and synthetic active substances, content test results tied to the Medicines (Prohibition of Sale and Supply) Order, and microbiological testing depending on whether the product is for oral consumption or external application. The microbiological organisms and counts listed (e.g., Escherichia coli, Salmonella, Staphylococcus aureus, yeast and mould counts, and aerobic microbial counts) are accompanied by carve-outs where the product contains active substances derived from plants/animals and produced by fermentation processes. The licensing authority may also require “such other documents and test results” as it considers necessary.
3. Grant of licences (Section 4). While the extract truncates the text of Section 4, the structure indicates that Section 4 governs how licences are granted and what conditions attach upon grant. For practitioners, Section 4 is typically where the Regulations connect the standard provisions to the licensing decision—i.e., that licences are granted subject to the standard provisions and any additional requirements the licensing authority may impose under the Medicines Act framework.
4. Fees and evaluation costs (Sections 5 and 5A). Section 5 provides for fees in respect of applications for, and the grant of, licences and certificates (and related administrative items). The Fifth Schedule contains the fee table. Section 5A introduces cost of evaluation, which is significant for budgeting and for anticipating additional charges beyond application fees—particularly where regulatory assessment requires technical review.
5. Offences and enforcement (Section 6). Section 6 provides that a holder of a licence who contravenes or fails to comply with any standard provision applicable to the holder commits an offence. This is a key compliance hook: standard provisions are not merely “guidance”; they are enforceable conditions. For counsel advising regulated businesses, the practical implication is that breach risk should be managed as a matter of criminal/regulatory exposure, not only administrative non-compliance.
How Is This Legislation Structured?
The Regulations are structured as follows:
(i) Sections 1–6 set out the citation, definitions, the standard provisions framework, licensing grant mechanics, fees, evaluation costs, and offences.
(ii) Schedules provide the detailed standard provisions and fee amounts:
- First Schedule: Standard provisions for product licence
- Second Schedule: Standard provisions for import licence
- Third Schedule: Standard provisions for wholesale dealer’s licence
- Fourth Schedule: Standard provisions for manufacturer’s licence
- Fifth Schedule: Fees
- Sixth Schedule: Repealed (historical material)
For legal work, the schedules are often where the “real” obligations live. A practitioner should therefore read the relevant schedule alongside the relevant section that incorporates it (notably Section 3).
Who Does This Legislation Apply To?
The Regulations apply to persons or entities that seek or hold licences under Part II of the Medicines Act. This includes businesses involved in: (a) product licensing (typically the entity responsible for the medicinal product’s regulatory standing), (b) importing medicines into Singapore, (c) wholesale dealing/distribution, and (d) manufacturing medicines.
The Regulations also apply differently depending on the type of medicine. The extract makes clear that Chinese proprietary medicines are subject to modified standard provisions for import licences (and corresponding modifications for wholesale dealer’s and manufacturer’s licences). Accordingly, a company’s compliance programme must be tailored to both (i) the licence type it holds and (ii) the category of medicinal product it deals with.
Why Is This Legislation Important?
For practitioners, the Regulations are important because they convert licensing into a set of standard, enforceable conditions. Many compliance failures in regulated industries are not about whether a licence exists, but about whether the licence holder complied with the conditions attached to that licence. Section 6 makes this explicit by creating offences for contravention or failure to comply with standard provisions.
From a commercial and operational perspective, the Regulations also drive compliance systems. The Chinese proprietary medicine provisions demonstrate how regulatory requirements translate into concrete workflows: approvals must be sought before dealing with products; documents and microbiological test results must be generated and submitted within statutory timeframes (e.g., within two months of import); and exemptions may apply only where specified production methods are used. These are the kinds of details that, if missed, can lead to enforcement action.
Finally, the fee and evaluation cost provisions matter for transaction planning and regulatory strategy. When advising on market entry, product launches, or supply chain changes, counsel should anticipate both application/grant fees (Section 5 and Fifth Schedule) and possible evaluation costs (Section 5A). This affects timelines, cost estimates, and internal approvals for regulatory submissions.
Related Legislation
- Medicines Act (Cap. 176), including Section 74 (authorising provision for these Regulations)
- Medicines (Prohibition of Sale and Supply) Order (O 4) (referenced for test results on specified substances)
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (O 6) (referenced for the definition of “Chinese proprietary medicine”)
- Medicines (Export Licence for Psychotropic Substances) Regulations (Rg 9) (referenced for definition of “psychotropic substance”)
- Poisons Act (Cap. 234) (referenced for declarations regarding absence of poison)
Source Documents
This article provides an overview of the Medicines (Licensing, Standard Provisions and Fees) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.